GSK 315234

Drug Profile

GSK 315234

Alternative Names: 315234; GSK315234; GSK315234A

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Oncostatin M modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 21 Oct 2009 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in Rheumatoid arthritis presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top